RxDoctor Payments Data

Tara Frankhouser, DO

Family Medicine · Statesville, NCNPI 1841553815

Payments from drug & device makers

$3,545in general payments, 2019–2025

Across 193 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$780
  • AbbVie$349
  • Lundbeck LLC$347
  • AstraZeneca$266
  • Lilly USA, LLC$229
  • Inspire Medical Systems, Inc.$210
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,545 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$52,707
Medicare patients
97
Services billed
6,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$87,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$27,903
MounjaroTirzepatide17$22,637
RybelsusSemaglutide15$21,750
EliquisApixaban17$21,308
MyrbetriqMirabegron15$19,747
JardianceEmpagliflozin17$14,538
ShingrixVaricella-Zoster Ge/As01b/Pf22$4,916
VyvanseLisdexamfetamine Dimesylate11$4,836
Dexlansoprazole DrDexlansoprazole11$4,373
Boostrix TdapDiphth,pertuss(Acell),tet Vac28$1,965
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,749
Rosuvastatin Calcium151$1,707
Azelastine Hcl39$1,608
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen54$1,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$780$109,34860 claims
GSKTrelegy Ellipta, Shingrix$78$32,81942 claims
Lilly USA, LLCMounjaro$229$22,63717 claims
PfizerEliquis$140$21,30817 claims
Boehringer IngelheimJardiance$50$14,53817 claims
AbbVieSynthroid$349$58312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →